Sermorelin Acetate

114466-38-5

C149H246N44O42S

BVLCEKWPOSAKSZ-YQMCHIOTSA-N

3417.9 g/mol

3416.843184 g/mol

Bulk Drug Intermediates

1510 Ų

5.07090

GHRH analog (1–29 amino-terminal fragment, 29-amino-acid peptide amide)

FDA-approved diagnostic agent (Geref, discontinued). NOT for therapeutic use.

A synthetic 29-amino-acid peptide (H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂) identical to the amino-terminal segment of endogenous human GHRH. Sermorelin binds to the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, stimulating pulsatile GH synthesis and secretion via the cAMP/PKA pathway. Unlike exogenous GH, sermorelin preserves the endogenous GH pulsatility and IGF-1 feedback loop.

~0.1–1 nM (cAMP accumulation in rat pituitary cells)

DrugBank: DB00010. Frohman LA, et al. Endocr Rev. 1986;7(3):223–253.DOI

NCT00001390; NCT00527397

Geref (approved 1991-10-11)

CHEMBL1201555

DB00010

D08554

PubChem

FDA: Geref (NDA 019863, discontinued)

Sermorelin was FDA-approved as a diagnostic agent (Geref) for growth hormone deficiency but has been discontinued (not for safety reasons). It is NOT approved for anti-aging, bodybuilding, or therapeutic GH replacement. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.